JPWO2020249796A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249796A5 JPWO2020249796A5 JP2021573885A JP2021573885A JPWO2020249796A5 JP WO2020249796 A5 JPWO2020249796 A5 JP WO2020249796A5 JP 2021573885 A JP2021573885 A JP 2021573885A JP 2021573885 A JP2021573885 A JP 2021573885A JP WO2020249796 A5 JPWO2020249796 A5 JP WO2020249796A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazin
- phenyl
- fluoro
- difluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 29
- 230000000155 isotopic effect Effects 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 29
- 239000012453 solvate Substances 0.000 description 29
- 150000001204 N-oxides Chemical class 0.000 description 28
- -1 isotopic variant Chemical class 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 4
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IOVODVUWRRUOKI-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OCCC1)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OCCC1)=O)OC(F)F IOVODVUWRRUOKI-UHFFFAOYSA-N 0.000 description 2
- WKLSJWREWGANFJ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)OC(F)F WKLSJWREWGANFJ-UHFFFAOYSA-N 0.000 description 2
- KZMPDDVHWIESKP-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)F KZMPDDVHWIESKP-UHFFFAOYSA-N 0.000 description 2
- ZVGWHQFTALTBJE-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)F ZVGWHQFTALTBJE-UHFFFAOYSA-N 0.000 description 2
- XEGOSSDWMDXZTG-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCCC1)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCCC1)=O)F XEGOSSDWMDXZTG-UHFFFAOYSA-N 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- UEUYPQCJJFPDRK-UHFFFAOYSA-N CN(C)C(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(Cl)C(OC(F)F)=C2)C(=O)O1 Chemical compound CN(C)C(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(Cl)C(OC(F)F)=C2)C(=O)O1 UEUYPQCJJFPDRK-UHFFFAOYSA-N 0.000 description 1
- LZGLKFBOGFAKRT-UHFFFAOYSA-N CN(C)C(=O)C1CN(CC2=NC(=CN=C2)C2=CC=C(F)C(=C2)C(C)(F)F)C(=O)O1 Chemical compound CN(C)C(=O)C1CN(CC2=NC(=CN=C2)C2=CC=C(F)C(=C2)C(C)(F)F)C(=O)O1 LZGLKFBOGFAKRT-UHFFFAOYSA-N 0.000 description 1
- YCFHEPDCXRJNPG-UHFFFAOYSA-N CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(Cl)C(OC(F)F)=C2)C(=O)O1 Chemical compound CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(Cl)C(OC(F)F)=C2)C(=O)O1 YCFHEPDCXRJNPG-UHFFFAOYSA-N 0.000 description 1
- SHGSSAGEEMBMMH-UHFFFAOYSA-N CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(F)C(=C2)C(F)F)C(=O)O1 Chemical compound CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(F)C(=C2)C(F)F)C(=O)O1 SHGSSAGEEMBMMH-UHFFFAOYSA-N 0.000 description 1
- KFODIVVLBDMLJL-UHFFFAOYSA-N CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(F)C(OC(F)F)=C2)C(=O)O1 Chemical compound CNC(=O)C1CN(CC2=CN=CC(=N2)C2=CC=C(F)C(OC(F)F)=C2)C(=O)O1 KFODIVVLBDMLJL-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- PXZWRQUMIVVXJV-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)OC(F)F PXZWRQUMIVVXJV-UHFFFAOYSA-N 0.000 description 1
- YGVRCZRRVIHJAX-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)OC(F)F YGVRCZRRVIHJAX-UHFFFAOYSA-N 0.000 description 1
- NRGSIHZZNDZYRY-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)OC(F)F NRGSIHZZNDZYRY-UHFFFAOYSA-N 0.000 description 1
- OKBWBAPYQVDQQP-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)OC(F)F OKBWBAPYQVDQQP-UHFFFAOYSA-N 0.000 description 1
- NXELEXWMOSZDLC-VIFPVBQESA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)OC(F)F NXELEXWMOSZDLC-VIFPVBQESA-N 0.000 description 1
- NXELEXWMOSZDLC-SECBINFHSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)OC(F)F NXELEXWMOSZDLC-SECBINFHSA-N 0.000 description 1
- FQHDYWVAFGIVSP-SECBINFHSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)OC(F)F FQHDYWVAFGIVSP-SECBINFHSA-N 0.000 description 1
- FQHDYWVAFGIVSP-VIFPVBQESA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)OC(F)F FQHDYWVAFGIVSP-VIFPVBQESA-N 0.000 description 1
- PUOSICQCSZJYPF-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CN(C2)C)OC1=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CN(C2)C)OC1=O)OC(F)F PUOSICQCSZJYPF-UHFFFAOYSA-N 0.000 description 1
- QWBSMGVELKDPIS-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CNC2)OC1=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CC2(CNC2)OC1=O)OC(F)F QWBSMGVELKDPIS-UHFFFAOYSA-N 0.000 description 1
- HFYVNPRQZFPQFH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)OC(F)F HFYVNPRQZFPQFH-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- GCPWCSZFZMNPKB-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1C(OC(C1)(C)C)=O)C Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1C(OC(C1)(C)C)=O)C GCPWCSZFZMNPKB-UHFFFAOYSA-N 0.000 description 1
- FUGCHCVBALVZDO-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C FUGCHCVBALVZDO-UHFFFAOYSA-N 0.000 description 1
- VYWIDDWHSQWJIW-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C VYWIDDWHSQWJIW-UHFFFAOYSA-N 0.000 description 1
- RWAYZNXDRJCVCJ-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O RWAYZNXDRJCVCJ-UHFFFAOYSA-N 0.000 description 1
- LIKWIEJAKJGCAW-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(OCCC1)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(OCCC1)=O LIKWIEJAKJGCAW-UHFFFAOYSA-N 0.000 description 1
- UJNMJERYEYGLSD-LLVKDONJSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O UJNMJERYEYGLSD-LLVKDONJSA-N 0.000 description 1
- UJNMJERYEYGLSD-NSHDSACASA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O UJNMJERYEYGLSD-NSHDSACASA-N 0.000 description 1
- ADMRMXBMQQWROK-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O ADMRMXBMQQWROK-UHFFFAOYSA-N 0.000 description 1
- AHBCQOSOOAJGBO-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O Chemical compound FC(C)(F)C=1C=C(C=CC=1)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O AHBCQOSOOAJGBO-UHFFFAOYSA-N 0.000 description 1
- VBCKDJVPJWAAMI-JTQLQIEISA-N FC(C)(F)C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O VBCKDJVPJWAAMI-JTQLQIEISA-N 0.000 description 1
- VBCKDJVPJWAAMI-SNVBAGLBSA-N FC(C)(F)C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O VBCKDJVPJWAAMI-SNVBAGLBSA-N 0.000 description 1
- QEPVNOGWJPMOQI-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OCCC1)=O)C)F QEPVNOGWJPMOQI-UHFFFAOYSA-N 0.000 description 1
- NABQDFIWOVWIHA-VIFPVBQESA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@@H]1C)=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@@H]1C)=O)C)F NABQDFIWOVWIHA-VIFPVBQESA-N 0.000 description 1
- NABQDFIWOVWIHA-SECBINFHSA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@H]1C)=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@H]1C)=O)C)F NABQDFIWOVWIHA-SECBINFHSA-N 0.000 description 1
- FABLWHASOJDQPL-SECBINFHSA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@@H](C1)C)=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@@H](C1)C)=O)C)F FABLWHASOJDQPL-SECBINFHSA-N 0.000 description 1
- FABLWHASOJDQPL-VIFPVBQESA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@H](C1)C)=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@H](C1)C)=O)C)F FABLWHASOJDQPL-VIFPVBQESA-N 0.000 description 1
- QRRATDPCRSYZPC-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)F QRRATDPCRSYZPC-UHFFFAOYSA-N 0.000 description 1
- JOBJGHNBRAIWDC-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)F JOBJGHNBRAIWDC-UHFFFAOYSA-N 0.000 description 1
- UXWHJSHLOUHNQO-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)F UXWHJSHLOUHNQO-UHFFFAOYSA-N 0.000 description 1
- XLEKQFXQIUWWBZ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCC1)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCC1)=O)F XLEKQFXQIUWWBZ-UHFFFAOYSA-N 0.000 description 1
- IEJOMSKSRUEBQK-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCCC1)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCCC1)=O)F IEJOMSKSRUEBQK-UHFFFAOYSA-N 0.000 description 1
- VWBYIDAJHOHANQ-VIFPVBQESA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)F VWBYIDAJHOHANQ-VIFPVBQESA-N 0.000 description 1
- VWBYIDAJHOHANQ-SECBINFHSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)F VWBYIDAJHOHANQ-SECBINFHSA-N 0.000 description 1
- BDIHREPQSBFVIU-SECBINFHSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)F BDIHREPQSBFVIU-SECBINFHSA-N 0.000 description 1
- BDIHREPQSBFVIU-VIFPVBQESA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)F BDIHREPQSBFVIU-VIFPVBQESA-N 0.000 description 1
- IZMYRZLHGZYRKQ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)F IZMYRZLHGZYRKQ-UHFFFAOYSA-N 0.000 description 1
- MUIXYTNXRYQXCZ-UHFFFAOYSA-N FC(F)C1=CC(=CC=C1F)C1=NC(CN2CC(OC2=O)C(=O)N2CCC2)=CN=C1 Chemical compound FC(F)C1=CC(=CC=C1F)C1=NC(CN2CC(OC2=O)C(=O)N2CCC2)=CN=C1 MUIXYTNXRYQXCZ-UHFFFAOYSA-N 0.000 description 1
- DWKMMTBRJCNNJY-UHFFFAOYSA-N FC(F)OC1=CC(=CC=C1F)C1=NC(CN2CC(OC2=O)C(=O)N2CCC2)=CN=C1 Chemical compound FC(F)OC1=CC(=CC=C1F)C1=NC(CN2CC(OC2=O)C(=O)N2CCC2)=CN=C1 DWKMMTBRJCNNJY-UHFFFAOYSA-N 0.000 description 1
- SDRFOGCMLSEYJR-VIFPVBQESA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@@H]1C)=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@@H]1C)=O)C)F SDRFOGCMLSEYJR-VIFPVBQESA-N 0.000 description 1
- SDRFOGCMLSEYJR-SECBINFHSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@H]1C)=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(OC[C@H]1C)=O)C)F SDRFOGCMLSEYJR-SECBINFHSA-N 0.000 description 1
- NKWLWBQEQSQEQT-SECBINFHSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@@H](C1)C)=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@@H](C1)C)=O)C)F NKWLWBQEQSQEQT-SECBINFHSA-N 0.000 description 1
- NKWLWBQEQSQEQT-VIFPVBQESA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@H](C1)C)=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1C(O[C@H](C1)C)=O)C)F NKWLWBQEQSQEQT-VIFPVBQESA-N 0.000 description 1
- LVNLQZDHINQWHE-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CC2(CC2)OC1=O)C)F LVNLQZDHINQWHE-UHFFFAOYSA-N 0.000 description 1
- AOQOYSSCJVREII-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C(C(=N1)CN1CCC2(CC2)OC1=O)C)F AOQOYSSCJVREII-UHFFFAOYSA-N 0.000 description 1
- YEUMMFWCLBAXQO-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC(C1)(C)C)=O)F YEUMMFWCLBAXQO-UHFFFAOYSA-N 0.000 description 1
- DWSGBKTVKGVFRI-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCC1)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OCC1)=O)F DWSGBKTVKGVFRI-UHFFFAOYSA-N 0.000 description 1
- BHBDFWUVPWLGOF-VIFPVBQESA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@@H]1C)=O)F BHBDFWUVPWLGOF-VIFPVBQESA-N 0.000 description 1
- BHBDFWUVPWLGOF-SECBINFHSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(OC[C@H]1C)=O)F BHBDFWUVPWLGOF-SECBINFHSA-N 0.000 description 1
- YTMYFHIXMXDDNC-SECBINFHSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@@H](C1)C)=O)F YTMYFHIXMXDDNC-SECBINFHSA-N 0.000 description 1
- YTMYFHIXMXDDNC-VIFPVBQESA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1C(O[C@H](C1)C)=O)F YTMYFHIXMXDDNC-VIFPVBQESA-N 0.000 description 1
- YLFLPFCZGJXJDF-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CC2(CC2)OC1=O)F YLFLPFCZGJXJDF-UHFFFAOYSA-N 0.000 description 1
- IWFHGBXQEIILKO-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=CC(=N1)CN1CCC2(CC2)OC1=O)F IWFHGBXQEIILKO-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- VTCUTMCWUZJDHX-UHFFFAOYSA-N N1(CCC1)C(=O)C1CN(C(O1)=O)CC1=NC(=CN=C1)C1=CC(=C(C=C1)Cl)OC(F)F Chemical compound N1(CCC1)C(=O)C1CN(C(O1)=O)CC1=NC(=CN=C1)C1=CC(=C(C=C1)Cl)OC(F)F VTCUTMCWUZJDHX-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861642P | 2019-06-14 | 2019-06-14 | |
| US62/861,642 | 2019-06-14 | ||
| PCT/EP2020/066396 WO2020249796A1 (en) | 2019-06-14 | 2020-06-12 | Pyrazine carbamates and their use as glun2b receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538795A JP2022538795A (ja) | 2022-09-06 |
| JP2022538795A5 JP2022538795A5 (https=) | 2023-06-21 |
| JPWO2020249796A5 true JPWO2020249796A5 (https=) | 2023-06-21 |
Family
ID=71108570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573885A Withdrawn JP2022538795A (ja) | 2019-06-14 | 2020-06-12 | ピラジンカルバメート及びＧｌｕＮ２Ｂ受容体調節因子としての使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11459336B2 (https=) |
| EP (1) | EP3983072A1 (https=) |
| JP (1) | JP2022538795A (https=) |
| KR (1) | KR20220020915A (https=) |
| CN (1) | CN113950357A (https=) |
| AU (1) | AU2020290772A1 (https=) |
| BR (1) | BR112021023562A2 (https=) |
| CA (1) | CA3142998A1 (https=) |
| MX (1) | MX2021015511A (https=) |
| WO (1) | WO2020249796A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) * | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| AU2001270149A1 (en) | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CA2482838A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CN101842357A (zh) | 2007-08-30 | 2010-09-22 | 武田药品工业株式会社 | 取代的吡唑衍生物 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| WO2009118187A1 (en) | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| NZ590688A (en) | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| EP2570415B1 (en) | 2011-09-19 | 2015-08-26 | Sanofi | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| SG11201506687RA (en) | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
-
2020
- 2020-06-12 CN CN202080043609.0A patent/CN113950357A/zh active Pending
- 2020-06-12 KR KR1020227001088A patent/KR20220020915A/ko not_active Withdrawn
- 2020-06-12 US US16/899,817 patent/US11459336B2/en active Active
- 2020-06-12 WO PCT/EP2020/066396 patent/WO2020249796A1/en not_active Ceased
- 2020-06-12 BR BR112021023562A patent/BR112021023562A2/pt not_active Application Discontinuation
- 2020-06-12 JP JP2021573885A patent/JP2022538795A/ja not_active Withdrawn
- 2020-06-12 MX MX2021015511A patent/MX2021015511A/es unknown
- 2020-06-12 EP EP20733714.8A patent/EP3983072A1/en not_active Withdrawn
- 2020-06-12 AU AU2020290772A patent/AU2020290772A1/en not_active Abandoned
- 2020-06-12 CA CA3142998A patent/CA3142998A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531020A5 (https=) | ||
| JP2021510695A5 (https=) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JPWO2020249796A5 (https=) | ||
| JP2019525939A5 (https=) | ||
| JP2014502982A5 (https=) | ||
| JP2012515166A5 (https=) | ||
| JP2017509676A5 (https=) | ||
| JP2020517607A5 (https=) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2018508592A5 (https=) | ||
| JP2017502063A5 (https=) | ||
| JP2013507374A5 (https=) | ||
| JP2011525185A5 (https=) | ||
| JP2020504156A5 (https=) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| JP2015536965A5 (https=) | ||
| JPWO2020249799A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2012532858A5 (https=) | ||
| JP2017503804A5 (https=) | ||
| JP2017525684A5 (https=) | ||
| JP2019535715A5 (https=) | ||
| JP2020507592A5 (https=) | ||
| JPWO2023139534A5 (https=) |